Charles River Laboratories shows strong revenue, earnings gains in Q1

By The Science Advisory Board staff writers

May 4, 2021 -- Sales gains across all three of its business segments helped drive Charles River Laboratories to a 16.6% increase in revenue in its 2021 first quarter.

Charles River had first-quarter revenue of $824.6 million, up from $707.1 million reported in the first quarter of 2020. The company's research models and services segment produced a 21.2% increase in revenue, while the discovery and safety assessment segment climbed 14.2% and the manufacturing and support segment generated a 19.7% increase in revenues. Overall, the contract research organization had first-quarter net income of $61.5 million, compared with $50.8 million a year ago.

Based on the strong first quarter, Charles River is raising its forecast for the year. The company said it now expects to achieve 2021 revenue growth of 19%-21%, up from the previous expectation of 16%-18% growth. Nongenerally accepted accounting principles (GAAP) earnings per share is also now expected to range between $9.75-$10, up from the prior forecast of $9-$9.25, Charles River said.

Charles River to provide clients with Valence AI tech
Charles River Laboratories and Valence Discovery have formed a strategic partnership to provide clients with access to Valence's artificial intelligence...
Charles River acquires Retrogenix for $48M
Charles River Laboratories has paid approximately $48 million U.S. to acquire the U.K.-based contract research organization Retrogenix.
Charles River to pay $875M to buy Cognate BioServices
Charles River Laboratories has signed a deal to pay about $875 million in cash to acquire cell and gene manufacturer Cognate BioServices.
Charles River, Cypre collaborate on in vitro services
Charles River Laboratories is joining forces with Cypre to advance the understanding of the tumor microenvironment and predict therapeutic efficacy. Charles...
Charles River Laboratories acquires Distributed Bio
Charles River Laboratories has acquired Silicon Valley-based antibody drug discovery firm Distributed Bio for $83 million in cash.

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter